On Dec 18, vtv Therapeutics Got Notice From Hangzhou Zhongmei Huadong Pharmaceutical Of Intent To Terminate License Agreement Dated Dec 21,2017; Termination Of Agreement Will Not Be Effective Until After Both Parties Negotiate And Finalize
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics received a notice from Hangzhou Zhongmei Huadong Pharmaceutical indicating their intent to terminate a license agreement from December 21, 2017. The termination will not be effective until both parties negotiate and finalize the terms, according to an SEC filing.
December 22, 2023 | 9:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
vTv Therapeutics has been notified by Hangzhou Zhongmei Huadong Pharmaceutical of their intention to terminate a license agreement from 2017. The process requires negotiation and finalization before it takes effect.
The notice of intent to terminate a license agreement is likely to be viewed negatively by investors as it could signal potential loss of revenue or strategic partnerships for vTv Therapeutics. The impact is significant as the agreement dates back to 2017, indicating a potentially established relationship. However, the final effect on the stock will depend on the outcome of the negotiations and the terms of the termination.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100